GEORGE CHOLANKERIL to End Stage Liver Disease
This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about End Stage Liver Disease.
Connection Strength
4.624
-
Improved liver transplant outcomes for patients with hilar cholangiocarcinoma following implementation of the MMAT-3 policy. Liver Transpl. 2026 Jun 01; 32(6):823-829.
Score: 0.771
-
Pre-Operative Delta-MELD is an Independent Predictor of Higher Mortality following Liver Transplantation. Sci Rep. 2019 06 05; 9(1):8312.
Score: 0.494
-
Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci. 2017 10; 62(10):2915-2922.
Score: 0.434
-
Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices. Clin Gastroenterol Hepatol. 2017 02; 15(2):313-315.
Score: 0.408
-
Post-liver transplantation outcomes in acute-on-chronic liver failure: Impact of alcohol as a precipitant and etiology of chronic liver disease. Liver Transpl. 2026 Jan 01; 32(1):86-94.
Score: 0.190
-
Is the Transplantation of Elderly and DCD Donors in Low MELD Recipients Justified: An Intent-to-treat Analysis. Transplantation. 2025 05 01; 109(5):823-831.
Score: 0.180
-
Unseen foe: The financial toxicity of liver transplantation. Liver Transpl. 2024 09 01; 30(9):873-874.
Score: 0.174
-
Using noninvasive clinical parameters to predict mortality and morbidity after cardiac interventions in patients with cirrhosis: A systematic review. Saudi J Gastroenterol. 2024 01 01; 30(1):14-22.
Score: 0.168
-
Is Liver Transplant Justified at Any MELD Score? Transplantation. 2023 03 01; 107(3):680-692.
Score: 0.156
-
Changing trends in aetiology-based hospitalizations with end-stage liver disease in the United States from 2016 to 2019. Liver Int. 2022 11; 42(11):2390-2395.
Score: 0.154
-
Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease: A Review of the Literature With Recommendations. J Clin Gastroenterol. 2021 10 01; 55(9):747-756.
Score: 0.145
-
Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. Hepatology. 2021 12; 74(6):3316-3329.
Score: 0.145
-
Trends in Hospitalizations for Clostridioides difficile Infection in End-Stage Liver Disease, 2005-2014. Dig Dis Sci. 2021 01; 66(1):296-307.
Score: 0.130
-
The impact of chronic liver disease in patients receiving active pharmacological therapy for opioid use disorder: One-year findings from a prospective cohort study. Drug Alcohol Depend. 2020 04 01; 209:107917.
Score: 0.130
-
Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease. J Palliat Med. 2020 01; 23(1):97-106.
Score: 0.125
-
Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Liver Int. 2019 09; 39(9):1661-1671.
Score: 0.123
-
Disparate Trends in Mortality of Etiology-Specific Chronic Liver Diseases Among Hispanic Subpopulations. Clin Gastroenterol Hepatol. 2019 07; 17(8):1607-1615.e2.
Score: 0.119
-
Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy. Dig Dis Sci. 2018 Jun; 63(6):1647-1653.
Score: 0.114
-
Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol. 2018 Jan 21; 24(3):315-322.
Score: 0.112
-
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017 Dec 21; 23(47):8263-8276.
Score: 0.112
-
Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis. Nutrients. 2017 Oct 13; 9(10).
Score: 0.110
-
Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. Dig Dis Sci. 2016 09; 61(9):2505-15.
Score: 0.099
-
Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis. Hepatol Int. 2019 Jan; 13(1):84-90.
Score: 0.030